194 related articles for article (PubMed ID: 15110086)
1. Increased effects of MPDAX, a novel xanthine derivative, on antitumor activity of doxorubicin.
Sadzuka Y; Sugiyama T; Suzuki H; Sawanishi H; Miyamoto K
Toxicol Lett; 2004 May; 150(3):341-9. PubMed ID: 15110086
[TBL] [Abstract][Full Text] [Related]
2. Effects of glutamate transporter inhibitors on the antitumor activity of doxorubicin.
Sadzuka Y; Yamashita Y; Sonobe T
Clin Cancer Res; 2002 Dec; 8(12):3943-7. PubMed ID: 12473610
[TBL] [Abstract][Full Text] [Related]
3. Anserine induced advantage effects on the antitumor activity of doxorubicin.
Sadzuka Y; Sonobe T
Food Chem Toxicol; 2007 Jun; 45(6):985-9. PubMed ID: 17240507
[TBL] [Abstract][Full Text] [Related]
4. Screening of biochemical modulator by tumor cell permeability of doxorubicin.
Sadzuka Y; Hatakeyama H; Daimon T; Sonobe T
Int J Pharm; 2008 Apr; 354(1-2):63-9. PubMed ID: 18054183
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of doxorubicin concentration in the M5076 ovarian sarcoma cells by cucurbitacin E co-treatment.
Sadzuka Y; Hatakeyama H; Sonobe T
Int J Pharm; 2010 Jan; 383(1-2):186-91. PubMed ID: 19732815
[TBL] [Abstract][Full Text] [Related]
6. Enhanced efficacy of 1-methyl-3-propyl-7-butylxanthine on the antitumor activity of doxorubicin against doxorubicin-resistant P388 leukemia.
Sadzuka Y; Sugiyama T; Sawanishi H; Miyamoto K
Cancer Lett; 1999 Apr; 138(1-2):5-11. PubMed ID: 10378767
[TBL] [Abstract][Full Text] [Related]
7. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1.
Loadman PM; Bibby MC; Double JA; Al-Shakhaa WM; Duncan R
Clin Cancer Res; 1999 Nov; 5(11):3682-8. PubMed ID: 10589787
[TBL] [Abstract][Full Text] [Related]
10. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR
Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390
[TBL] [Abstract][Full Text] [Related]
11. Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo.
Yoshimoto Y; Kawada M; Ikeda D; Ishizuka M
Int Immunopharmacol; 2005 Feb; 5(2):281-8. PubMed ID: 15652759
[TBL] [Abstract][Full Text] [Related]
12. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
[TBL] [Abstract][Full Text] [Related]
13. Effect of linalool as a component of Humulus lupulus on doxorubicin-induced antitumor activity.
Miyashita M; Sadzuka Y
Food Chem Toxicol; 2013 Mar; 53():174-9. PubMed ID: 23220514
[TBL] [Abstract][Full Text] [Related]
14. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
[TBL] [Abstract][Full Text] [Related]
15. Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates.
Andersson L; Davies J; Duncan R; Ferruti P; Ford J; Kneller S; Mendichi R; Pasut G; Schiavon O; Summerford C; Tirk A; Veronese FM; Vincenzi V; Wu G
Biomacromolecules; 2005; 6(2):914-26. PubMed ID: 15762660
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.
Pastorino F; Di Paolo D; Piccardi F; Nico B; Ribatti D; Daga A; Baio G; Neumaier CE; Brignole C; Loi M; Marimpietri D; Pagnan G; Cilli M; Lepekhin EA; Garde SV; Longhi R; Corti A; Allen TM; Wu JJ; Ponzoni M
Clin Cancer Res; 2008 Nov; 14(22):7320-9. PubMed ID: 19010847
[TBL] [Abstract][Full Text] [Related]
17. A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy.
de Graaf M; Nevalainen TJ; Scheeren HW; Pinedo HM; Haisma HJ; Boven E
Biochem Pharmacol; 2004 Dec; 68(11):2273-81. PubMed ID: 15498517
[TBL] [Abstract][Full Text] [Related]
18. Effects of xanthine derivatives on the influx and efflux of doxorubicin in P388 and DOX-resistant P388 leukemia cells.
Sadzuka Y; Egawa Y; Sawanishi H; Miyamoto K; Sonobe T
Toxicol Lett; 2002 Sep; 135(1-2):137-44. PubMed ID: 12243872
[TBL] [Abstract][Full Text] [Related]
19. [The effect of finoptin on the accumulation of doxorubicin in leukemia P388 cells with induced resistance to the antibiotic].
Moroz LV; Donenko FV; Borovkova NB; Sitdikova SM
Biull Eksp Biol Med; 1989 Dec; 108(12):714-6. PubMed ID: 2634447
[TBL] [Abstract][Full Text] [Related]
20. Theanine and glutamate transporter inhibitors enhance the antitumor efficacy of chemotherapeutic agents.
Sugiyama T; Sadzuka Y
Biochim Biophys Acta; 2003 Dec; 1653(2):47-59. PubMed ID: 14643924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
